Metformin and cognition from the perspectives of sex, age, and disease

Research output: Contribution to journalReview article

Authors

External Institution(s)

  • University of North Texas Health Science Center

Details

Original languageEnglish (US)
Pages (from-to)97-116
Number of pages20
JournalGeroScience
Volume42
Issue number1
StatusPublished - Feb 1 2020
Peer-reviewedYes

Abstract

Metformin is the safest and the most widely prescribed first-line therapy for managing hyperglycemia due to different underlying causes, primarily type 2 diabetes mellitus. In addition to its euglycemic properties, metformin has stimulated a wave of clinical trials to investigate benefits on aging-related diseases and longevity. Such an impact on the lifespan extension would undoubtedly expand the therapeutic utility of metformin regardless of glycemic status. However, there is a scarcity of studies evaluating whether metformin has differential cognitive effects across age, sex, glycemic status, metformin dose, and duration of metformin treatment and associated pathological conditions. By scrutinizing the available literature on animal and human studies for metformin and brain function, we expect to shed light on the potential impact of metformin on cognition across age, sex, and pathological conditions. This review aims to provide readers with a broader insight of (a) how metformin differentially affects cognition and (b) why there is a need for more translational and clinical studies examining multifactorial interactions. The outcomes of such comprehensive studies will streamline precision medicine practices, avoiding “fit for all” approach, and optimizing metformin use for longevity benefit irrespective of hyperglycemia.

    Research areas

  • Age, Brain function, Cognition, Diabetes, Gender, Metformin, Sex

Citation formats

APA

Harvard